60 YEARS OF NEUROENDOCRINOLOGY

The hypothalamo-prolactin axis

David R Grattan1,2

1Centre for Neuroendocrinology and Department of Anatomy, University of Otago, PO Box 913, Dunedin 9054, New Zealand
2Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand

Abstract

The hypothalamic control of prolactin secretion is different from other anterior pituitary hormones, in that it is predominantly inhibitory, by means of dopamine from the tuberoinfundibular dopamine neurons. In addition, prolactin does not have an endocrine target tissue, and therefore lacks the classical feedback pathway to regulate its secretion. Instead, it is regulated by short loop feedback, whereby prolactin itself acts in the brain to stimulate production of dopamine and thereby inhibit its own secretion. Finally, despite its relatively simple name, prolactin has a broad range of functions in the body, in addition to its defining role in promoting lactation. As such, the hypothalamo-prolactin axis has many characteristics that are quite distinct from other hypothalamo-pituitary systems. This review will provide a brief overview of our current understanding of the neuroendocrine control of prolactin secretion, in particular focusing on the plasticity evident in this system, which keeps prolactin secretion at low levels most of the time, but enables extended periods of hyperprolactinemia when necessary for lactation. Key prolactin functions beyond milk production will be discussed, particularly focusing on the role of prolactin in inducing adaptive responses in multiple different systems to facilitate lactation, and the consequences if prolactin action is impaired. A feature of this pleiotropic activity is that functions that may be adaptive in the lactating state might be maladaptive if prolactin levels are elevated inappropriately. Overall, my goal is to give a flavour of both the history and current state of the field of prolactin neuroendocrinology, and identify some exciting new areas of research development.

Key Words
- prolactin
- tuberoinfundibular dopamine neurons
- pregnancy
- lactation
- prolactin-releasing factor

Introduction

When Geoffrey Harris wrote his influential monograph on 'Neural Control of the Pituitary Gland', it was already apparent that prolactin, or 'lactogenic hormone' as he referred to it, might be controlled differently to the other adenohypophyseal hormones. Harris convincingly built the case that humeral factors from the hypothalamus control secretion of anterior pituitary hormones, correctly predicting the existence of hypothalamic 'releasing factors' that mediate the neural control of pituitary secretions (Harris 1948). Despite the clear evidence that neural stimuli (such as suckling) could stimulate prolactin secretion, however, Harris noted that cutting the pituitary stalk did not abolish lactation (Dempsey & Uotila 1940), leading to the inevitable conclusion that a hypothalamic 'prolactin-releasing factor' was not necessary to stimulate prolactin secretion. Indeed, it was subsequently shown in hypophysectomised rats that ectopic pituitary grafts were able to maintain corpus luteum function (Everett 1954) and lactation (Cowie et al. 1960), demonstrating hypothalamic-independent secretion of prolactin from the grafts. At first impression, this appeared to contradict Harris’ principle of neural control of the anterior pituitary. But further observations identified the
fact that hypothalamic regulation was indeed critical for normal prolactin secretion, as Harris predicted, but that the mode of control was different. Everett found that while pituitaries located away from the hypothalamus would induce pseudopregnancy, a marker of elevated prolactin secretion in rodents, normal cycles (and therefore normal low levels of prolactin) would resume if transplanted pituitaries were re-vascularised by portal vessels under the median eminence (Nikitovitch-Winer & Everett 1958). Two groups independently demonstrated that extracts of the median eminence/infundibular region could inhibit prolactin secretion from anterior pituitary cells in vitro (Pasteels 1963, Talwalker et al. 1963). Subsequently, it was shown that median eminence lesions (Arimura et al. 1972) or destruction of the pituitary stalk (Kanematsu & Sawyer 1973) resulted in elevated prolactin secretion (accounting for the pseudopregnancies described earlier by Everett). Thus, it was proven that the hypothalamus was essential for the regulation of prolactin secretion, but that it primarily exerted an inhibitory influence.

This brief review will summarise our current understanding of the hypothalamic control of prolactin secretion, and the neuroendocrine functions of prolactin, highlighting (admittedly selected) areas of current research interest. From the somewhat contrary beginnings previously introduced, the neural control of prolactin secretion, and indeed the whole hypothalamo-prolactin axis, continues to prove itself a bit different from other hypothalamo-pituitary systems. Not only is the hypothalamic regulation predominantly inhibitory, as opposed to stimulatory, it also involves a catecholamine neurotransmitter, dopamine, rather than the more typical peptide hypothalamic hormones involved in regulating all other pituitary systems. Prolactin is also the only anterior pituitary hormone that does not have an endocrine target tissue, and therefore lacks a classical hormonal feedback system. It is regulated, instead, by a short loop feedback whereby prolactin itself stimulates the secretion of the inhibitory factor, dopamine. Finally, despite its rather simple and one-dimensional name, prolactin does much more than simply PROmote LACTation. It is now recognised as a pleiotrophic hormone with arguably the widest range of physiological actions of any extracellular signalling molecule in the body.

**Neuroendocrine control of prolactin secretion**

**Dopamine as a prolactin-inhibitory hormone**

Even after the clear demonstration of inhibitory regulation of prolactin secretion in the 1950s, the search for the inhibitory hormone mediating this action was controversial. All hypothalamic hormones identified to date had been peptides, and the expectation was that ‘prolactin-inhibitory factor’ would also be a peptide. Initial clues that this might not be the case came from observations that drugs such as reserpine, which depletes endogenous catecholamines, induced pseudopregnancy in rats (Barraclough & Sawyer 1959), indicative of elevated prolactin. It was assumed, however, that the functional role of catecholamines were as neurotransmitters acting in the hypothalamus to regulate the release of a hypothalamic hormone (Kanematsu et al. 1963). Based on the evidence of dopaminergic nerve terminals in the median eminence (Fuxe 1963), McLeod proposed that dopamine may be released into the pituitary portal system, and thereby acting as a hypothalamic hormone (as distinct from its neurotransmitter role in other systems) (MacLeod et al. 1970). He demonstrated that dopaminergic agonists were effective at suppressing prolactin secretion in vivo, and perhaps more importantly, that dopamine could inhibit prolactin secretion from isolated pituitary glands (MacLeod et al. 1970). Dopamine was subsequently detected in the pituitary portal blood (Kamberi et al. 1970), and Porter’s group (and others) found that variations of levels of dopamine in the portal blood accounted for changes in prolactin secretion in various physiological conditions (Ben-Jonathan et al. 1977, 1980, Gibbs & Neill 1978, De Greef & Neill 1979). Dopamine receptors were identified on lactotroph cells in the anterior pituitary (Mansour et al. 1990). The observation that mice lacking the dopamine D2 receptor are hyperprolactinemic (Kelly et al. 1997, Saiardi et al. 1997), clearly demonstrated the critical role of dopamine in suppressing endogenous prolactin secretion (see Fig. 1).

The dopamine neurons that control prolactin secretion are located within the arcuate nucleus of the hypothalamus. While it seems likely that they serve functionally as a single population, these neurons have been subdivided into three sub-populations based on the anatomy of their projections: the tuberoinfundibular (TIDA), tuberohypophyseal (THDA), and periventricular hypophyseal (PHDA) dopaminergic neurons (Freeman et al. 2000). TIDA neurons arise from the dorsomedial arcuate nucleus and project to the external zone of the median eminence (Bjorklund et al. 1973). The other two populations have their cell bodies located slightly more rostrally, but their projections pass in the hypothalamo-hypophyseal tract through the median eminence to the hypophysis. The THDA neurons originate in the rostral arcuate nucleus and project to the intermediate and neural lobes of the pituitary gland (Fuxe 1964, Holzbauer &
Racke 1985), while the PHDA neurons originate in the periventricular nucleus, with axons terminating in the intermediate lobe (Goudreau et al. 1992). The TIDA neurons produce the classical hypothalamic hormone secretion into the pituitary portal blood vessels, while THDA and PHDA neurons contribute to basal regulation of prolactin secretion, after transport of dopamine to the anterior pituitary gland through short portal vessels from the neurohypophysis (Peters et al. 1981). While anatomically distinct, there is considerable overlap in their dendritic fields (van den Pol et al. 1984), and all three populations appear to be regulated similarly. For example, all are stimulated by prolactin (DeMaria et al. 1999). Hence, it is reasonable to consider them as a functional unit of prolactin-inhibiting neurons.

Electrophysiological studies of hypothalamic dopamine neurons in the rat have described TIDA neurons as exhibiting a robust oscillation between hyperpolarized and depolarized states, with periodicity of about 20 s, and a spontaneous firing rate of ~4 Hz during the depolarized ‘up-state’. Remarkably, the TIDA neurons were found to show a synchronous pattern of firing suggestive of an interconnected network, dependent on functional expression of gap junctions (Lyons et al. 2010). Taking advantage of transgenic technologies to label dopaminergic neurons with fluorescent tags, studies of TIDA electrical activity have also been completed in brain slices from mice (Brown et al. 2012, Romano et al. 2013), showing a similar pattern of firing to that seen in the rat, although only a small proportion of TIDA neurons showed the phasic oscillations in this model. Importantly, one of these latter studies demonstrated that patterns of firing of an individual TIDA neuron were reflected in the pattern of dopamine release from the population, as measured using in vivo amperometry in the median eminence (Romano et al. 2013). These data support the concept postulated by Lyons et al. (2010), that the neurons act as a synchronous network to release dopamine in a pulsatile or phasic fashion.

**Figure 1**

Diagrammatic representation of the neuroendocrine regulation of prolactin secretion. Anterior pituitary prolactin release is inhibited by dopamine coming from the tuberoinfundibular dopamine neurons (shown in the coronal section on the top left using immunohistochemistry against tyrosine hydroxylase, brown) whose cell bodies are found in the arcuate nucleus of the hypothalamus, with axons projecting to the external layer of the median eminence. Images on the right show examples of both rapid feedback (electrophysiological activation) and delayed feedback (phosphorylation of STAT5, black nuclear staining) in TIDA neurons. In each example, 1) illustrates prior to prolactin treatment, and 2) after administration of prolactin (reproduced, with permission, from Brown RS, Piet R, Herbison AE & Grattan DR (2012) Differential actions of prolactin on electrical activity and intracellular signal transduction in hypothalamic neurons. *Endocrinology* 153 2375–2384. Copyright 2012 The Endocrine Society). Prolactin stimulates dopamine secretion, to inhibit its own secretion by short loop feedback.
Of the five dopamine receptors, the two members of the D2-like receptor family, D2 and D4 are found in the pituitary gland (Valerio et al. 1994, Matsumoto et al. 1995) and it is through these D2-like receptors that dopamine acts to inhibit lactotroph cell function (Mansour et al. 1990, Ben-Jonathan & Hnasko 2001). Uniquely among anterior pituitary cells, lactotrophs display spontaneous electrical activity in the absence of hypothalamic stimulation and Ca\(^{2+}\) influx through voltage-gated Ca\(^{2+}\) channels (VGCC) stimulates to prolactin secretion (Gregerson 2006). This accounts for the high levels of basal prolactin secretion, and is consistent with a regulatory mechanism primarily based on inhibition. Dopamine inhibits calcium influx resulting in membrane hyperpolarisation (Gregerson et al. 1994, Gregerson 2003) and reduced prolactin secretion (Lledo et al. 1990). In addition to its effect on secretion, dopamine-induced suppression of adenylate cyclase leads to a reduction in prolactin gene expression (Maurer 1982, Elsholtz et al. 1991, Ishida et al. 2007). Dopamine also has a significant role to regulate lactotroph proliferation, as demonstrated in cultures of pituitary cells (Ishida et al. 2007), as well as in vivo by suppression of oestriadiol-induced proliferation (Borgundvaag et al. 1992). When dopamine levels are increased, such as caused by the loss of the dopamine transporter, there is a severe post-natal reduction in lactotroph proliferation leading to a dramatic reduction in the number of lactotrophs by 8 weeks of age (Bosse et al. 1997). In contrast, there is marked lactotroph hyperplasia following loss of the D2 receptor (Kelly et al. 1997, Saiardi et al. 1997), leading to the formation of prolactinomas. This is exacerbated by age, and more prevalent in females than males (Saiardi et al. 1997, Asa et al. 1999). A bias towards lactotroph hyperplasia and more rapid generation of pituitary tumours in females may be expected from the direct actions of estradiol to stimulate prolactin production by lactotrophs, but this may not be the sole factor leading to the increased female hyperplasia. Gonadectomy has been shown to reduce lactotroph hyperplasia and tumour formation in D2 knockout mice, but that this could not be fully rescued by estradiol replacement, suggesting that ovarian factors other than estradiol may contribute to the proliferation of lactotrophs (Hentges & Low 2002).

Prolactin regulation of dopamine neurons: short loop feedback

As previously mentioned, the hypothalamo-prolactin system does not have a specific endocrine target, and therefore lacks the classical hormone-mediate negative feedback pathway described for all other anterior pituitary hormones. Nevertheless, it is still regulated in a negative feedback manner, with prolactin itself providing the afferent signal in a process known as short-loop feedback. The presence of prolactin receptors on dopamine neurons (Lerant & Freeman 1998, Grattan 2001, Kocay & Grattan 2005) was predicted by early neurochemical studies that showed that exogenous prolactin stimulated hypothalamic dopamine synthesis (Hokfelt & Fuxe 1972) and turnover (Eikenburg et al. 1977, Annunziato & Moore 1978), increased dopamine metabolism in the median eminence (Lookingland et al. 1987) and promoted dopamine secretion into the pituitary portal blood (Gudelsky & Porter 1979). In contrast, hypoprolactinaemia induced by administration of dopamine agonists resulted in suppression of dopamine secretion (Arbogast & Voogt 1991a), indicating that the basal activity of these neurons is dependent on the endogenous levels of prolactin present in the blood. Using these biochemical indices of activity of TIDA neurons, the time course of prolactin action was described as having a ‘rapid’ component of increased activity observed 2–4 h after prolactin treatment (Selmanoff 1985), and a delayed component seen ~12 h after prolactin treatment (Demarest et al. 1984a, 1986). More recent electrophysiological data has demonstrated even more rapid actions of prolactin on the electrical activity of TIDA neurons in mice (Brown et al. 2012, Romano et al. 2013) or rats (Lyons et al. 2012). These studies show that prolactin induces a fourfold increase in firing rate within seconds to minutes of application, acutely changing the firing pattern from a basal phasic pattern to a tonically active pattern. Hence, there seem to be multiple mechanisms of prolactin regulation of these dopamine neurons mediated over different time courses.

It was observed that prolactin feedback was markedly impaired in mice lacking the transcription factor STAT5b (Grattan et al. 2001), likely through impairment in the long-term regulation of expression of the rate limiting enzyme in dopamine synthesis, tyrosine hydroxylase (Arbogast & Voogt 1991a, Ma et al. 2005). While such an effect might account for the ‘delayed’ component of prolactin feedback, which requires protein synthesis (Johnston et al. 1980), it is unlikely to account for more rapid components of short look feedback. The very rapid action revealed by electrophysiology appears to involve two components: a low voltage component from transient receptor potential (TRP)-like current and high voltage component from inhibition of a Ca\(^{2+}\)-dependent BK-type K\(^+\) current, with the latter component being wortmannin sensitive, suggesting an involvement of the PI3K pathway (Lyons et al. 2012). The slower component, originally
Plasticity in prolactin feedback during lactation

In order to support a period of hyperprolactinemia during lactation, and thereby promote the milk production that is essential to this state, there is an apparent loss of sensitivity of the short-loop feedback system during late pregnancy and lactation (Grattan et al. 2008). This is a remarkable example of adaptive plasticity within a neuroendocrine control network, allowing a sustained period of high prolactin secretion to be maintained unencumbered by a regulatory feedback pathway (see Fig. 2). The mechanisms concerned with regulation of prolactin secretion may have been shown to simultaneously activate neurons throughout the hypothalamus (Brown et al. 2010, Sapsford et al. 2012), not simply in the arcuate nucleus. There is clear evidence that systemic prolactin crosses the blood-brain barrier through a saturable, carrier-mediated transport system (Walsh et al. 1987). As a result, prolactin levels in the cerebrospinal fluid parallel changes in prolactin in the peripheral circulation (Login & MacLeod 1977, Nicholson et al. 1980, Grattan & Averill 1991). Because of the high levels of prolactin receptor expression and prolactin binding seen in the choroid plexus (Walsh et al. 1978, 1990, Pi & Grattan 1998a, b, Augustin et al. 2003), it has been widely assumed that the prolactin receptor might mediate prolactin entry into the cerebrospinal fluid. However, we have recently shown that prolactin transport into the brain is independent of the prolactin receptor, occurring just as well in prolactin receptor knockout mice (Brown RSE, Wyatt AK, Herbison RE, Knowles PJ, Ladyman SR, Binart N, Banks WA & Grattan DR, unpublished observations). Hence, precise mechanism that translocates prolactin from the blood into the CSF remains to be determined.

For endogenous prolactin to function in the short-loop feedback manner, previously described, one important consideration is how this relatively large (197–199 amino acids; 21 kDa) polypeptide hormone crosses the blood-brain barrier to gain access to the dopamine neurons. While it is possible that the arcuate nucleus/median eminence region may have an incomplete blood-brain barrier such that hormones can directly access to neurons in this area (Schaeffer et al. 2013), it seems unlikely that this is the major mechanism by which prolactin regulates the hypothalamic dopamine neurons. Indeed, systemic administration of prolactin has been shown to simultaneously activate neurons throughout the hypothalamus (Brown et al. 2010, Sapsford et al. 2012), not simply in the arcuate nucleus. There is clear evidence that systemic prolactin crosses the blood-brain barrier through a saturable, carrier-mediated transport system (Walsh et al. 1987). As a result, prolactin levels in the cerebrospinal fluid parallel changes in prolactin in the peripheral circulation (Login & MacLeod 1977, Nicholson et al. 1980, Grattan & Averill 1991). Because of the high levels of prolactin receptor expression and prolactin binding seen in the choroid plexus (Walsh et al. 1978, 1990, Pi & Grattan 1998a, b, Augustin et al. 2003), it has been widely assumed that the prolactin receptor might mediate prolactin entry into the cerebrospinal fluid. However, we have recently shown that prolactin transport into the brain is independent of the prolactin receptor, occurring just as well in prolactin receptor knockout mice (Brown RSE, Wyatt AK, Herbison RE, Knowles PJ, Ladyman SR, Binart N, Banks WA & Grattan DR, unpublished observations). Hence, precise mechanism that translocates prolactin from the blood into the CSF remains to be determined.

Figure 2
(A) Diagrammatic representation of short loop feedback control of prolactin secretion. (B) Adaptive changes in the regulation of prolactin secretion during pregnancy and lactation. Note that there are multiple adaptive processes to ensure elevated levels of lactogenic hormones present both in the blood and in the brain of the mother, potentially regulating a wide range of functions to facilitate lactation: 1) Production of prolactin-like molecules from the placenta to bypass feedback regulation of pituitary prolactin secretion. 2) Plasticity in the TIDA neuronal response to prolactin, with reduced secretion of dopamine and induction of enkephalin expression. 3) Maternal behavioural adaptation to suckle the pups, providing the most powerful prolactin-releasing stimulus known. 4) Increased transport of prolactin into the brain during lactation.
mediating this adaptive response are only recently becoming elucidated. Up until late pregnancy in rodents, normal negative feedback regulation of prolactin secretion dominates, as previously described, but high levels of placental lactogens are produced. As placental lactogen binds to and activates prolactin receptors, this mimics prolactin action and bypasses the feedback inhibition to ensure that prolactin responsive functions are highly stimulated at this time. Activity of hypothalamic dopamine neurons is maintained by the presence of placental lactogen, so pituitary prolactin secretion is low. Despite the continued presence of placental lactogens, however, there is a decrease in activity of the dopamine neurons during late pregnancy (Andrews et al. 2001) associated with a nocturnal surge in pituitary prolactin secretion immediately before parturition (Grattan & Averill 1990, 1995). Hypothalamic dopamine neurons apparently no longer release dopamine in response to prolactin or placental lactogen at this time, rendering the short-loop negative feedback system functionally inactive (Grattan & Averill 1995, Fliestra & Voogt 1997). This adaptation persists into lactation, and dopamine secretion remains low throughout this period of elevated prolactin secretion (Ben-Jonathan et al. 1980, Demarest et al. 1983). This is an important adaptation, because prolactin is required for milk production and maternal behaviour at this time.

There is a highly coordinated release of prolactin during lactation, caused by the suckling stimulus. This is associated with a decrease in dopamine turnover in hypothalamic dopamine neurons (Selmanoff & Wise 1981, Demarest et al. 1983, Selmanoff & Gregerson 1985) and a profound suppression of tyrosine hydroxylase mRNA levels (Wang et al. 1993). The original perception that hypothalamic dopamine neurons show a ‘loss of response’ to prolactin at this time has proved to be incorrect. In fact, prolactin receptor expression in the dopamine neurons is maintained (Kokay & Grattan 2005), and acute electrophysiological responses to prolactin persist in lactation (Romano et al. 2013). Downstream of the prolactin receptor, however, there is a change in the cellular response. Serine 40 phosphorylation of tyrosine hydroxylase in the median eminence is decreased (Feher et al. 2010, Romano et al. 2013), resulting in a reduction in the activity of this enzyme (and a reduction in dopamine synthesis). Strikingly, there is a disconnection between neuronal firing and dopamine release at the median eminence. Even though the electrophysiological response to prolactin is unchanged, there is no longer detectable release of dopamine in the median eminence (Romano et al. 2013). Prolactin-induced activation of STAT5b in dopamine neurons is reduced during lactation, potentially mediated by an up-regulation of endogenous inhibitors of STAT signaling, the suppressors of cytokine signaling (SOCS) proteins (Anderson et al. 2006a,b, Steyn et al. 2008). At the same time as the loss of dopamine secretion, there is an increase in met-enkephalin expression in the dopamine neurons (Merchenthaler 1993, 1994, Szabo et al. 2011), and it seems possible that elevated prolactin may drive this met-enkephalin expression (Nahi & Arbogast 2003). Hence, the neurons essentially change their phenotype, changing from being dopaminergic to enkephalinergic. As they still respond electrophysiologically to prolactin, they may be mediating a completely different function of prolactin in the brain during lactation.

It is interesting to note that while the suckling-induced prolactin secretion could be consistent with the ‘dopamine withdrawal’ or ‘disinhibition’ model of prolactin secretion, previously discussed, the chronic reduction in dopamine output seen during lactation complicates this interpretation. If dopamine production is lost, as implied in the data of Romano et al. (2013), how can suckling cause an acute increase in prolactin secretion through dopamine withdrawal? Perhaps this is evidence that a suckling-induced ‘prolactin-releasing factor’ may be involved in stimulating prolactin secretion at this time (see further discussion of prolactin-releasing factors in the following section). It is well established that enkephalin can promote prolactin secretion (Cusan et al. 1977), and while most evidence suggests that this effect is mediated centrally through regulation of TIDA neurons, it can also act in the pituitary gland to antagonize dopaminergic inhibition of lactotrophs (Enjalbert et al. 1979). Could the lactation-specific release of enkephalin from TIDA neurons be functioning as a prolactin-releasing factor, either in the classical sense, by regulating lactotroph function via the portal blood, or through a more local effect on TIDA neurons within the median eminence? Either way, the idea that prolactin might be promoting its own secretion through the same neurons that normally inhibits its secretion, essentially switching from negative to positive feedback at a time when high levels of prolactin are required, is a provocative one worthy of further investigation.

Some significant insight has been provided by recent advances in mapping the neuronal pathways conveying the suckling stimulus through to specific neuronal populations within the hypothalamus. A direct neuronal pathway is involved, transmitting the somatosensory afferent information from the nipple via the spinal cord to the hypothalamus (Berghorn et al. 2001). Recent evidence suggests that there is a direct pathway from the...
subparafascicular nucleus and posterior thalamus to the ventrolateral arcuate nucleus, possibly connecting with the dynorphin neurons located in this region (Szabo et al. 2011). Neurons in this pathway express the peptide tuberoinfundibular peptide of 39 residues (TIP39), and this peptide may be a critical regulator of prolactin secretion in response to suckling (Cservenak et al. 2010, Dobolyi 2011), acting through the parathyroid hormone 2 receptor (Dobolyi et al. 2012) to suppress activity of TIDA neurons.

**Role of a ‘prolactin-releasing factor’?**

Ever since Harris’ first proposal of the humeral control of the anterior pituitary gland, researchers have searched for a ‘prolactin-releasing factor’ to match that of other pituitary hormones. There have been some notable discoveries, but to date, convincing evidence for a physiological prolactin-releasing factor has not been forthcoming (for reviews, see Freeman et al. (2000), Ben-Jonathan & Hnasko (2001) and Crowley (2015)).

Most of the factors that regulate prolactin secretion do so by directly or indirectly influencing dopamine secretion from the hypothalamic dopamine neurons. The best example of this is prolactin itself, which stimulates dopamine release to inhibit its own secretion (previously discussed). Other examples are opioid peptides, which are potent stimulators of prolactin secretion, and act predominately through an inhibition of dopamine neurons. Alternatively, factors may stimulate prolactin secretion through an action on the pituitary gland. The ovarian steroid, estradiol, is an excellent example, acting on lactotrophs to increase prolactin gene expression and increase levels of prolactin released in response to other stimuli (Fink 1988). Neither of these actions would classify as a hypophysiotrophic ‘prolactin releasing factor’, as defined by Harris. For this, the factor would need to be produced in the hypothalamus, be secreted into the portal blood, and act in the pituitary gland to stimulate prolactin secretion (and thereby oppose the actions of the hypothalamic inhibitory hormone).

The levels of prolactin achieved by administration of dopamine antagonists are as high as one would normally associate with prolactin release stimulated under physiological conditions, such as in response to the suckling stimulus (Andrews & Grattan 2004). Thus, it would seem possible to account for most stimulated prolactin secretion simply by a process of disinhibition, removing the normal dopaminergic inhibitory control. However, whether such a total withdrawal of dopamine ever occurs in vivo is unlikely (Martinez de la Escalera & Weiner 1992). There is continued interest in the possibility that a physiological ‘prolactin-releasing factor’ exists. Vasoactive intestinal polypeptide (VIP) may be the ancestral regulator of prolactin secretion, since it is the primary ‘prolactin-releasing factor’ in non-mammalian vertebrates (Horsemann 1995), and it has stimulatory effects on prolactin secretion in mammals (Murai et al. 1989). However, while produced in both the hypothalamus and in the pituitary gland, it is unlikely that VIP acts as a hypophysiotrophic releasing factor, in the sense defined by Harris. It does not appear to be secreted into the portal system at levels higher than in the systemic circulation, nor is it present at elevated levels in the blood at all times that prolactin secretion is high. The same is probably true for a large number of factors that have been investigated as putative ‘prolactin releasing hormones’, including thyrotropin-releasing hormone, oxytocin, galanin, salsolinol, prolactin-releasing peptide and others (reviewed in Freeman et al. (2000), Crowley (2015) and Grattan & LeTissier (2015)). Many of these factors may influence prolactin secretion, either from effects on hypothalamic dopamine neurons, or from effects on pituitary lactotrophs, but none have proven to meet the criteria to be considered hypothalamic hypophysiotrophic factors.

Freeman’s group tackled this question by investigating whether changes in prolactin could be observed independently of dopaminergic inhibition. They observed that administration of the D2 antagonist domperidone induced different levels of prolactin secretion at different times of the day (Arey et al. 1989). Assuming that antagonism of dopamine was complete at each time point, they interpreted these data to demonstrate the existence of an ‘endogenous stimulatory rhythm’, where factors from the hypothalamus (including oxytocin and VIP) were promoting prolactin secretion at specific times in dependently of dopamine (Arey & Freeman 1990, 1992a,b), but this stimulation was usually masked by the prevailing dopaminergic tone. Importantly, they also showed that endogenous stimuli that reduce dopamine input to the pituitary, such as suckling, could also reveal this stimulatory rhythm, promoting different levels of prolactin secretion at different times of the day (Arey et al. 1991). These data provide convincing evidence of dopamine-independent regulation of prolactin secretion, but cannot conclusively prove it is mediated by a ‘prolactin-releasing factor’. An alternative possibility is that endogenous circadian regulators within the pituitary gland might influence that amount of prolactin released at different times of the day (Becquet et al. 2014).
Circadian regulation of prolactin secretion has also been documented via melatonin actions in the pars tuberalis (Lincoln et al. 2003).

If there is a physiological ‘prolactin-releasing factor’, it remains elusive. One possible reason for this is that the stimulatory control exerted from the hypothalamus may not be a ‘classical’ system, as defined by Harris. In the late 1980s and early 1990s, there was a particularly well-developed story regarding a putative prolactin-releasing factor coming from a subpopulation of melanotrophs in the intermediate lobe of the pituitary, as opposed to the median eminence. This factor was originally discovered by Murai & Ben-Jonathan (1987, 1990), who showed that surgical removal of the posterior pituitary (including the intermediate lobe) impaired the prolactin release in response to estradiol administration or suckling. This was subsequently supported by a number of other groups, with studies demonstrating reduced or absent prolactin secretion after removal of the neurointermediate lobe (Samson et al. 1990, Averill et al. 1991, Andrews & Grattan 2004). Moreover, mice with secretory tumours of the intermediate lobe were hyperprolactinemic (Allen et al. 1995). Despite extensive effort at characterisation, particularly from the Ben-Jonathan group, the specific identity of this factor (or factors) has not been identified, although a number of known prolactin secretagogues (TRH, oxytocin, VIP) were excluded (Allen et al. 1995, Hnasko et al. 1997). Nevertheless, this highlights the possibility that ‘non classical’ prolactin releasing systems may remain to be discovered.

Based on the magnitude of prolactin release in response to dopamine inhibition (Andrews & Grattan 2004), I have previously held the view that most prolactin release could be accounted for by a decrease in dopamine. Our new data showing that even after marked reductions in dopamine secretion during lactation in mice (Romano et al. 2013), there is a sustained ability to regulate prolactin secretion in response to suckling, however, has forced a re-think of this view. It would seem that other regulatory factors must be involved in the physiological regulation of prolactin secretion, particularly during lactation when it is most required. Whether one or more of these factors becomes the long sought ‘prolactin-releasing factor’ predicted by Harris remains an exciting area needing further investigation.

Regulation of prolactin secretion by estradiol

The ovarian steroid estradiol is arguably one of the most important regulators of prolactin secretion in several different physiological states. In the pituitary gland, estradiol is a major stimulator of prolactin secretion, although this is principally through a classical genomic regulation of prolactin gene expression (Lieberman et al. 1981), by increasing the number of lactotrophs (Takahashi et al. 1984, Scully et al. 1997, Kansra et al. 2005, 2010, Nolan & Levy 2009) and by modifying lactotroph responsiveness to other regulators (De Lean & Labrie 1977, Raymond et al. 1978, West & Dannies 1980), although a rapid non-genomic actions of estradiol stimulating prolactin secretion have been described (Huerta-Ocampo et al. 2005). The TIDA neurons also express receptors for both estradiol (estrogen receptor alpha (ERα)) and progesterone (Sar 1984, 1988, Fox et al. 1990, Lonstein & Blaustein 2004, Steyn et al. 2007), and gonadal steroids regulate prolactin secretion indirectly through actions on these neurons (Jones & Naftolin 1990, Arbogast & Voogt 1993, 1994, DeMaria et al. 2000). These actions of estradiol are particularly important during the reproductive cycle and during pregnancy. The predominant direct action of estradiol on TIDA neurons is one of inhibition (Demarest et al. 1984b, Arita & Kimura 1987, DeMaria et al. 2000, Morel et al. 2009), suppressing TH expression (Blum et al. 1987, Morrell et al. 1989) and activity (Pasqualini et al. 1993), and reducing secretion of dopamine into the portal blood (Cramer et al. 1979), thereby facilitating prolactin secretion. The estradiol-induced proestrous prolactin surge is associated with a steroid-dependent decline in TIDA activity (DeMaria et al. 1998, Yen & Pan 1998, Liu & Arbogast 2008, 2010), with a prominent role for progesterone suppressing dopamine release during the plateau phase of the surge (Arbogast & Ben-Jonathan 1990, Arbogast & Voogt 1994). Similarly, ovarian steroids play a critical role in controlling the two-daily prolactin surges required to sustain luteal function pregnancy in rodents (Gunnet & Freeman 1983, Arbogast & Voogt 1991b). The rising levels of estradiol during pregnancy are also critical to promoting prolactin secretion, particularly during late pregnancy (Grattan & Averill 1990, Andrews 2005), and to the plasticity in the TIDA neurons as previously described (Grattan et al. 2008). In addition to regulation of prolactin secretion, estradiol may also regulate the cellular responses to prolactin. In the brain, many of the neurons expressing the prolactin receptor also express ERα (Furugo et al. 2014). Estradiol may regulate prolactin receptor expression on neurons (Lerant & Freeman 1998), and several of the actions of prolactin are dependent on the presence of estradiol (Anderson et al. 2008). Thus, estradiol acts at multiple levels to both directly and indirectly regulate prolactin synthesis, secretion and action.
Neuroendocrine functions of prolactin

Prolactin was identified and named for its critical role in the physiology of lactation, and this remains its best-characterised function. Prolactin is indispensable for lactation. However, a vast array of additional functions has also been characterised. These have been thoroughly reviewed by Paul Kelly’s group (Bole-Feyso et al. 1998), who classified the functions under six broad headings: water and electrolyte balance, growth and development, endocrinology and metabolism, brain and behaviour, reproduction and immune regulation and protection. The breadth of potential functions is astounding and difficult to conceptualise into a theoretical framework. Many of the reported actions of prolactin appear to be redundant, as evidenced by the lack of a significant phenotype in the prolactin or prolactin-receptor knockout mice. This may simply be the evolutionary result of a phylogenically old signalling molecule being used for multiple adaptive roles in homeostasis. One can see examples where prolactin has subserved similar functions across many species. For example, in fish and amphibia, it is involved in electrolyte balance, and movement of ions and water across epithelial barriers (Bole-Feyso et al. 1998). Perhaps this is not so different from inducing secretion of nutrients and electrolytes from an epithelial gland, as in the crop milk of pigeons, and the breast milk of mammals. Similarly, prolactin has been implicated in parental behaviour ranging from nest fanning in fish, through to incubation and brooding behaviour in birds, to lactation and maternal behaviour in mammals. When viewed from an evolutionary context, it seems logical that the nurturing parental behaviour actions of prolactin might have evolved in parallel with a nutrient synthesis and secretion role, providing an adaptive advantage of novel reproductive strategies.

There is insufficient space in this review to do justice to the wide range of potential prolactin-sensitive functions. Instead, I have taken the strategy of focusing on functions that are specifically regulated when endogenous prolactin levels are high. Apart from the estrogen-induced prolactin surge during the female reproductive cycle (which may not occur in all species (Ben-Jonathan et al. 2008), and the response to stress, which is transient and of low magnitude (Gala 1990)), prolactin levels are typically maintained at low levels as a consequence of the highly effective short loop negative feedback. The exception to this is pregnancy and lactation, where mammals exhibit at least three adaptations to ensure high levels of lactogenic hormone activity throughout these conditions (see Fig. 2). First, there is the production of placental lactogen and/or decidual prolactin, lactogens from reproductive tissues. These hormones act on the prolactin receptor, and therefore bypass the short-loop feedback regulation of the anterior pituitary gland to provide constantly elevated levels of lactogenic hormones throughout pregnancy. Secondly, there are the adaptive changes in feedback occurring in the maternal hypothalamic dopamine neurons, previously discussed, changing the manner in which they respond to prolactin, enabling high secretion to prolactin to be maintained from the maternal pituitary after the pregnancy-specific placental lactogens are lost at parturition. Thirdly, there is the hormone-dependent expression of maternal behavior, with the consequent suckling stimulus from the pups providing the most powerful stimulus to pituitary prolactin secretion that is known in mammals. As previously discussed, this might involve chronic and/or acute dopamine withdrawal, as well as the additional stimulus of an as yet unidentified ‘prolactin-releasing factor’ to maintain elevated levels of prolactin. Finally, we have recent evidence suggesting that transport of prolactin into the brain is increased during lactation (Brown RSE, Wyatt AK, Herbison RE, Knowles PJ, Ladyman SR, Binart N, Banks WA & Grattan DR, unpublished observations), suggesting that many of the CNS functions of prolactin might be further enhanced at this time. These multiple adaptive changes make a compelling argument to focus on pregnancy and lactation as the most critical time for prolactin actions in the body.

It is absolutely clear that these elevated levels of lactogenic hormones are required for development of the mammary gland during pregnancy and for milk production during lactation. The regulation of mammary function by prolactin is extensively reviewed elsewhere (Hovey et al. 2001, Trott et al. 2012). It is important to recognize, however, that prolactin and placental lactogen are also able to act in a wide variety of other tissues in the body. The prolactin receptor is widely expressed in numerous body systems, including bone, adipose tissue, gut, reproductive tract, skin, immune system, pituitary and brain (Bole-Feyso et al. 1998, Goffin et al. 2002), and hence, when prolactin is elevated there is potential for a wide variety of systems to be influenced. In recent reviews (Grattan & Kokay 2008, Grattan & LeTissier 2015), we have proposed the hypothesis that the wide range of potential actions of prolactin in the body make some collective sense if considered within the context of the physiological hyperprolactinemic state of pregnancy and lactation. These are complex and demanding processes for a mother, requiring multiple diverse systems to undergo adaptive changes to facilitate her successful transition.
from the non-pregnant into the maternal state. A selection of these adaptive changes, and a summary of the evidence that prolactin might influence the adaptive response, are outlined in Table 1. Here, prolactin can be considered as interoceptive sensory information for the body, informing it of its new physiological state. The changes it induces are adaptive, which means that the functions are unlikely to completely fail in the absence of prolactin action, but they might not perform optimally. This would account for the absence of widespread adverse phenotype in the prolactin

**Table 1** Role of prolactin in the maternal adaptation to pregnancy

<table>
<thead>
<tr>
<th>Tissue or function</th>
<th>Adaptive change during pregnancy</th>
<th>Evidence for possible role of prolactin?</th>
<th>Selected references</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammary gland/lactation</td>
<td>Branching and alveolar development of mammary gland</td>
<td>Unequivocal role, with lactation lost in Prlr−/− mice</td>
<td>Ormandy et al. (1997) and Trott et al. (2012)</td>
</tr>
<tr>
<td>Maternal behaviour</td>
<td>Retrieval and nursing of pups</td>
<td>Prolactin advances maternal responsiveness to pups in rats</td>
<td>Rosenblatt (1967), Bridges et al. (1985, 1990, 1996) and Bridges &amp; Ronsheim (1990)</td>
</tr>
<tr>
<td>Adult neurogenesis</td>
<td>Increased neurogenesis in the subventricular zone of the maternal brain</td>
<td>Impairs behaviour in Prlr−/− mice</td>
<td>Lucas et al. (1998)</td>
</tr>
<tr>
<td>Pancreatic β cell/glucose homeostasis</td>
<td>Maternal tissues become insulin resistant to promote glucose transfer to fetus</td>
<td>Driven by prolactin changes post partum</td>
<td>Shingo et al. (2003)</td>
</tr>
<tr>
<td></td>
<td>Expansion of beta cells in mother to increase insulin production, to prevent gestational diabetes</td>
<td>Important for mood and behavioural changes post partum</td>
<td>Larson et al. (2008) and Larsen &amp; Grattan (2010, 2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolactin receptors expressed in beta cells, and expression increased during pregnancy</td>
<td>Moldrup et al. (1993), Sorenson &amp; Stout (1995) and Breitje et al. (2004)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolactin stimulates insulin expression, secretion and beta cell proliferation</td>
<td>Kamin et al. (2007)</td>
</tr>
<tr>
<td>Appetite regulation</td>
<td>Increased appetite and development of leptin resistance</td>
<td>Prolactin stimulates food intake in non-pregnant animals</td>
<td>Huang et al. (2009), Kim et al. (2010), Rieck &amp; Kaestner (2010), Schraenen et al. (2010) and Zhang et al. (2010)</td>
</tr>
<tr>
<td>Bone and calcium homeostasis</td>
<td>Increased calcium uptake and mobilisation of calcium stores for fetal skeletal growth and for milk production</td>
<td>Prolactin contributes to appetite drive during lactation</td>
<td>Augustine &amp; Grattan (2008), Ladyman (2008) and Ladyman et al. (2010)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolactin receptors on osteoblasts and chondrocytes</td>
<td>Woodside et al. (2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolactin stimulates bone turnover</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolactin promotes calcium absorption in the gut</td>
<td></td>
</tr>
<tr>
<td>Reproduction</td>
<td>Maintenance of pregnancy (in rodents).</td>
<td>Prolactin stimulates corpus luteum function in rodents, essential to maintain pregnancy</td>
<td>Gibori &amp; Richards (1978) and Bachelot et al. (2009)</td>
</tr>
<tr>
<td></td>
<td>Loss of reproductive cycle during pregnancy, persisting during lactation</td>
<td>Hyperprolactinemia causes infertility Possible/likely involvement in lactational infertility</td>
<td>Patel &amp; Bamigboye (2007)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolactin is anxiolytic and reduced stress responses in males and non-pregnant females</td>
<td>McNeilly (2001a,b) and Liu et al. (2014)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Role during pregnancy and lactation likely, but unproven</td>
<td>Shanks et al. (1999), Torner et al. (2001), Lonstein (2007) and Brunton &amp; Russell (2008)</td>
</tr>
<tr>
<td>Stress responses</td>
<td>Reduced response to stress during late pregnancy and lactation, to minimise exposure of offspring to glucocorticoids</td>
<td>Prolactin receptors on oxytocin neurons, and acute inhibitory effects on activity</td>
<td>Torner &amp; Neumann (2002) and Slattery &amp; Neumann (2008)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulation of oxytocin gene expression</td>
<td>Kokay et al. (2006) and Sapsford et al. (2011)</td>
</tr>
<tr>
<td>Oxytocin secretion</td>
<td>Marked change in firing pattern, generation of ‘burst’ firing to facilitate parturition and milk ejection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolactin continues to stimulate TIDA neurons, but dopamine secretion is decreased</td>
<td>Parker et al. (1991) and Ghosh &amp; Sladek (1995a,b)</td>
</tr>
<tr>
<td>Prolactin secretion</td>
<td>Altered feedback to facilitate prolactin secretion</td>
<td>Induction of enkephalin production in TIDA</td>
<td>Grattan et al. (2008) and Romano et al. (2013)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Merzenthaler et al. (1994) and Nahi &amp; Arbogast (2003)</td>
</tr>
</tbody>
</table>
receptor knockout mice. It is appropriate to point out that many of the associations shown in Table 1 are, at this stage, correlative only, and comprehensive investigation proving that prolactin may be mediating a particular adaptive change will require significant further work. Nevertheless, we have found this to be a useful construct for understanding why prolactin might be influencing such a wide range of biological function. We used to be concerned by the question of, ‘Why would there be over 300 physiological actions of prolactin?’ Now, we can consider each of the different tissues that express the prolactin receptor and ask the question, ‘Why might this tissue need to change its function during lactation?’

Comprehensive reviews of the wide range of actions of prolactin in the body are available elsewhere (Bole-Feyssot et al. 1998, Freeman et al. 2000), as is our hypothesis regarding the role of prolactin in the physiological adaptation to pregnancy (Grattan & Kokay 2008, Grattan & LeTissier 2015), and hence, I will not go into detail here. In the final section of this review, I would like to briefly highlight three selected examples from recent research. The first of these, the metabolic functions of prolactin, nicely illustrates the context previously outlined that prolactin is acting in a number of different tissues and cell types in the mother to facilitate adaptation to pregnancy or lactation. The second example, looking at prolactin effects on fertility, highlights how functions of prolactin that might be considered adaptive in a lactating female, might be maladaptive should high prolactin occur at an inappropriate time. The third example asks the question, ‘What is prolactin doing in the male?’ This example is used to acknowledge the fact that some of the known functions of prolactin do not comfortably fit into the conceptual framework previously presented.

Metabolic function of prolactin

This is, perhaps, the best example of the pleiotropic role of prolactin (defined to mean a single gene product, prolactin, exerting multiple seemingly diverse actions). Prolactin receptors are expressed on multiple tissues involved in metabolic regulation, including adipose tissue, liver, pancreas and the brain. It appears to play a broad role in both pancreatic and adipose development. In adipose tissue, prolactin is essential in adipogenesis and adipocyte differentiation, as well as modulating lipid metabolism. It also regulates the secretion is several adipokines, including stimulation of leptin and inhibition of adiponectin production (Ben-Jonathan et al. 2006, Carre & Binart 2014). In the pancreas, it promotes growth of islets during development (Freemark et al. 2002), and increases insulin expression and glucose-stimulated insulin secretion (Sinha & Sorenson 1993, Brelje et al. 1994, 2004). It also increases expression of glucose transporter 2 and promotes glucose entry into the β-cells (Petryk et al. 2000), resulting in enhanced activity of glucose-sensitive enzymes such as glucokinase (Weinhaus et al. 2007). In both adipose tissue and pancreas, these actions are likely to be profoundly important during pregnancy and lactation. Lipid metabolism is altered, with lipid mobilisation from stores and utilisation in mammary gland promoted by prolactin (Barber et al. 1992). Adaptive changes in glucose homeostasis are also important in pregnancy (Rieck & Kaestner 2010). Maternal tissues develop insulin resistance to preferentially direct glucose to the fetal/placental compartment (Herrera 2000), and to ensure the maternal tissues continue to receive the nutrients required, there is increased demand for maternal insulin secretion, and glucose-stimulated insulin secretion increases. To adapt to this altered demand, there is significant proliferation of β-cells in the islets (Parsons et al. 1992), enhanced insulin synthesis (Bone & Taylor 1976), and decreased threshold for glucose-stimulated insulin secretion (Sorenson & Parsons 1985), with prolactin playing a critical adaptive role in promoting these changes (Newborn & Freemark 2011). Failure of this adaptive response results in gestational diabetes (Ramos-Roman 2011).

These peripheral actions of prolactin on metabolism are complemented by CNS actions of prolactin to promote appetite and potentially regulate glucose homeostasis. Systemic prolactin administration increases food intake in a variety of species (Moore et al. 1986, Gerardo-Gettens et al. 1989, Noel & Woodside 1993, Buntin et al. 1999), independent of potential effects on ovarian steroids (Noel & Woodside 1993, 2007, Sauvé & Woodside 1996). Thus, the elevated prolactin secretion is likely to contribute to the rapid increase in food intake during pregnancy (Shirley 1984, Ladyman & Grattan 2004, Ladyman et al. 2012) and the extreme hyperphagia of lactation (Woodside 2007, Woodside et al. 2012). Prolactin also induces functional leptin resistance, which would contribute to increased food intake (Naef & Woodside 2007, Augustine & Grattan 2008), potentially mediating the well-established leptin resistance of pregnancy (Grattan et al. 2007a, Augustine et al. 2008, Ladyman 2008, Ladyman et al. 2010). Prolactin receptors are found in many of the nuclei involved in the homeostatic regulation of food intake, including the arcuate, ventromedial and paraventricular nuclei (Bakowska & Morrell 1997, Pi & Grattan 1998b, Brown et al. 2010). However, prolactin receptors do not appear to be expressed in the arcuate neuropeptide Y (NPY) and...
proopiomelanocortin (POMC) neurons (Li et al. 1999, Chen & Smith 2004, Kokay & Grattan 2005) that regulate appetite. Hence, it seems likely that prolactin acts downstream of the arcuate neurons, such as at the paraventricular nucleus. Consistent with this hypothesis, localised injections of prolactin directly into the paraventricular nucleus stimulate food intake in a dose-dependent manner in female rats (Sauvé & Woodside 2000).

Thus, seemingly diverse actions of prolactin in multiple different cell types can be unified into a single adaptive function, which is metabolic adaptation to pregnancy, increasing energy availability to the mother and offspring. This is an example of the conceptual framework previously outlined, and it can be viewed as a positive, adaptive mechanism. Should hyperprolactinaemia occur at an inappropriate time, however, then one might predict this could contribute to metabolic disorders. There is some evidence for this. While it is not universally observed, patients with hyperprolactinaemia are prone to excessive weight gain (Creemers et al. 1991, Delgrange et al. 1999, Doknic et al. 2002, Baptista et al. 2004), and normalisation of prolactin levels using dopamine agonists is associated with weight loss (Greenman et al. 1998, Doknic et al. 2002, Galluzzi et al. 2005). Interestingly, genome-wide association studies have revealed that a common variant adjacent to the prolactin gene is associated with obesity (Meyre et al. 2009, Nilsson et al. 2011) suggesting that abnormalities in prolactin or prolactin signalling may contribute to human obesity.

**Hyperprolactinaemia and infertility**

Hyperprolactinaemia causes infertility in both males and females (Patel & Bamigboye 2007), and this provides an even more clear-cut example of a potentially adaptive function under certain conditions becoming clearly maladaptive in another situation. The mechanism by which prolactin inhibits the reproductive axis is not clear, but evidence suggests that prolactin impacts fertility through actions on GnRH neurons. In humans, hyperprolactinaemia is associated with a marked reduction in both the frequency and amplitude of LH pulses in male and female rats (Cohen-Becker et al. 1986, Fox et al. 1987, Park & Selmanoff 1991, Park et al. 1993) and measurements of GnRH secretion into the portal blood have revealed prolactin-induced suppression of GnRH release (Weber et al. 1983, Koike et al. 1984, 1991, Sarkar et al. 1992). Furthermore, hyperprolactinaemia has been shown to prevent the castration-induced increase in GnRH mRNA expression in rats (Selmanoff et al. 1991). Thus, although there is ample evidence that prolactin can act in the pituitary gland to suppress LH secretion (Smith 1978, 1982, Cheung 1983, Morel et al. 1994, Tortonese et al. 1998), in animal models, as in clinical studies, the primary cause of infertility appears to be the suppression of the activity of GnRH neurons. This effect of prolactin is unlikely to be mediated directly by an action on GnRH neurons, as the majority of these neurons do not express the prolactin receptor (Grattan et al. 2007b, Kokay et al. 2011). Thus, prolactin-induced inhibition of GnRH neurons must involve prolactin-sensitive afferents to these cells. Interestingly, most prolactin responsive neurons also express Erz (Furigo et al. 2014), so prolactin may share a common mechanism of regulating GnRH with the negative feedback pathway mediated by estradiol. As such, kisspeptin neurons have emerged as the most likely intermediate regulators.

Since first being identified as essential for puberty in humans (de Roux et al. 2003, Seminara et al. 2003), kisspeptin neurons are now recognised as critical parts of the circuit regulating activity of the GnRH neurons that control fertility (Pinilla et al. 2012). Kisspeptin neurons may have an important role in mediating the suppressive effect of prolactin on fertility. Kisspeptin is the most potent stimulator of GnRH neuronal activity yet identified (Han et al. 2005, Liu et al. 2008). In most mammalian species, there are two populations of kisspeptin neurons, with kisspeptin neurons in the rostral periventricular area of the third ventricle (RP3V) playing an essential role in enabling ovulation in rodents by activating GnRH neurons (Herbison 2008, Clarkson & Herbison 2009, Oakley et al. 2009), while kisspeptin neurons in the arcuate nucleus are thought to be involved in the regulation of the basal pulsatile secretion of GnRH (Li et al. 2009, Roseweir et al. 2009, Lehman et al. 2010, Navarro et al. 2011). Prolactin receptors are expressed in the majority of kisspeptin neurons in both populations (Kokay et al. 2011, Li et al. 2011), and prolactin has recently been shown to induce the phosphorylation of signal transducer and activator of transcription 5 (pSTAT5) in arcuate nucleus kisspeptin neurons in the rat.
(Araujo-Lopes et al. 2014) and rostral hypothalamic kisspeptin neurons in the mouse (Brown et al. 2014). Chronic infusion of prolactin in female mice abolished estrous cyclicity and suppressed global GnRH and Kiss1 mRNA expression in the hypothalamus, while kisspeptin therapy restored estrous cycles in hyperprolactinemic mice (Sonigo et al. 2012), consistent with the hypothesis that prolactin-induced suppression of GnRH secretion is mediated by an inhibition of kisspeptin neurons.

Clearly, under most conditions, hyperprolactinemia represents a pathological condition with adverse consequences. During pregnancy and lactation, however, hyperprolactinemia is physiologically appropriate. When viewed from this context, an inhibitory action of prolactin on fertility during pregnancy and lactation would be highly adaptive, allowing the mother to focus energy on feeding her offspring, before investing resources in a further pregnancy (Valeggia & Ellison 2009). Lactation is associated with a period of infertility in most mammalian females, including women (McNeilly 2001a). In humans, this function serves as a critical regulator of population growth, spacing the timing of births to allow the mother to ration her metabolic investment across sequential pregnancies (Short 1976). Despite the extensive impact on mammalian reproductive physiology, our understanding of the mechanisms mediating lactational infertility remains incomplete (McNeilly 1994, 2001a,b). It is clear that suckling is the critical inhibitory signal (Tsukamura & Maeda 2001), and the principle cause of infertility is an almost-complete suppression of the pulsatile secretion of GnRH from the hypothalamus, the consequent loss of pituitary gonadotropin secretion and ovulation failure (Fox & Smith 1984). The pathways linking the suckling stimulus to the suppression of ovulation, however, are unclear. Kiss1 mRNA and protein levels are reduced in the arcuate nucleus of lactating rats associated with the suppression of pulsatile GnRH secretion during lactation (Yamada et al. 2007, 2012, Smith et al. 2010, True et al. 2011, Araujo-Lopes et al. 2014, Ladyman & Woodside 2014), and in both populations in the mouse (Brown et al. 2014). The RP3V kisspeptin population is harder to study (Brown et al. 2007, 2012, Smith et al. 2007) and of kisspeptin protein remaining unchanged during lactation (Yamada et al. 2007) and of kisspeptin protein increasing while Kiss1 mRNA labeling decreased during lactation (Smith et al. 2010). More importantly, we have also shown that the reduction in kisspeptin expression results in complete loss of capability for these neurons to activate GnRH neurons, even if they are stimulated exogenously (Liu et al. 2014). Given the similarity between the effect of suckling and the effect of prolactin, and the knowledge that suckling stimulates prolactin secretion, it seems likely that elevated prolactin during pregnancy and lactation contributes to the infertility of lactation, but this remains to be proven, and the relative roles of prolactin and/or suckling may be different in different species.

What does prolactin do in the male?

The hypothesis that most prolactin actions in the body can be tied to the adaptation to pregnancy and lactation clearly does not explain effects of prolactin in the male. Up to 40% of the male pituitary gland is dedicated to lactotrophs, suggesting that some function is retained in males, but knockout studies have not identified an essential function of prolactin. While there is no male equivalent of lactation, many of the other functions of prolactin in females can also be observed in males. For example, as in females, prolactin seems to be involved in parental behaviour in males, although the relative role that the mammalian father plays in parental care of offspring varies amongst species. In species where the male plays some role in rearing of the offspring, including humans (Gordon et al. 2010, Gettler et al. 2012), studies have found a association between prolactin and paternal care (Schradin & Anzenberger 1999), although the overall picture is unclear and controversial (Schradin 2007, Wynne-Edwards & Timonin 2007). Nevertheless, paternal recognition of offspring is consistent amongst most species. Pup-contact by male rats can lead to some forms of parental care behaviour and this is associated with an increase in serum prolactin, as well as increased expression of the long-form of the prolactin receptor in the brain (Sakaguchi et al. 1996). Further evidence for a direct role for prolactin in paternal recognition of offspring has been shown by studies of Ptrl−/− fathers, who fail to distinguish adult offspring from non-offspring, possibly as a result of failure of prolactin-induced neurogenesis in the sub-ventricular zone and the dentate gyrus (Mak & Weiss 2010).

As in females, pathological hyperprolactinemia causes infertility in males, but it is not clear that there is an adaptive role for prolactin in male reproduction. At lower levels, prolactin contributes a range of functions in the male reproductive tract, revealed by subtle reproductive deficits in the prolactin receptor deficient mice (Grattan & LeTissier 2015). In addition, many of the metabolic and immune functions of prolactin can be observed in males, but whether prolactin levels are ever sufficient for these effects to be of physiological significance is uncertain. Perhaps the most consistent stimulus for prolactin secretion in males is stress,
but the functional consequences of this response are not well-understood (Gala 1990).

Conclusion

While Harris was correct in proposing that the brain controls prolactin secretion, the hypothalamo-prolactin axis proved itself to be quite different from all other pituitary systems. It remains the most complex and versatile of all of the hypothalamo-pituitary axes. Even if we just consider the relatively simple task of controlling milk production during lactation, there is much that remains to be understood, such as the possible role of one or more prolactin-releasing factors during the suckling stimulus, and the mechanism controlling the loss of dopamine production in the TIDA neurons and the changes in prolactin negative feedback. If we include the wide range of additional functions of prolactin, then the complexity becomes overwhelming. I have presented here a context to attempt to understand the pleiotropic roles of prolactin, arguing that many of the functions of prolactin can be unified into the overall task of maternal adaptation to pregnancy and lactation. Within this context, prolactin function promotes adaptive changes in a variety of body systems, but such actions can also be maladaptive, in a different context, if hyperprolactinemia occurs at an inappropriate time. This theoretical construct presents many new opportunities for generating testable hypotheses about prolactin function. But there are also many functions that do not fit easily into this construct, providing further opportunities for expanding our understanding. I anticipate that the coming availability of novel tools for investigating prolactin function, including gene-targeting approaches that allow conditional regulation of prolactin responsive cells, will provide the impetus for a new wave of research to enhance our understanding of this fascinating system. Sixty years on from Geoffrey Harris’ prescient predictions, we still have a lot of work to do to understand the hypothalamo-prolactin system.

Footnote

This paper is part of a thematic review section on 60 years of neuroendocrinology. The Guest Editors for this section were Ashley Grossman and Clive Coen.

Declaration of interest

The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

Prof. D. R. Grattan is supported by research grants from the New Zealand Health Research Council and the Marsden Fund of the Royal Society of New Zealand.

References


Arbogast LA & Voogt JL 1991a Hyperprolactinemia increases and hypoproprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta. *Endocrinology* **128** 997–1005. (doi:10.1210/endo-128-2-997)


Elsholz HP, Lew AM, Albert PR & Sundmark VC 1991 Inhibitory control of prolactin and Pit-1 gene promoters by dopamine. Dual signaling


Gibbs DM &Neill JD 1978 Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo. Endocrinology 102 1895–1900. (doi:10.1210/endo-102-6-1895)


Received in final form 18 June 2015
Accepted 22 June 2015
Accepted Preprint published online 22 June 2015